Molecular Testing Becoming Essential in AML Treatment
Dr. DeAngelo, Chief, Division of Leukemia, Institute Physician, Professor of Medicine, Harvard Medical School, explains the significance of the updated survival data for gilteritinib in acute myeloid leukemia (AML)
Published: 03 June 2019
The published content on this page is not directed by any sponsors and is at the sole discretion of Caribou Publishing and the OBR editorial staff.
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.